← AGIO: big moves and long-term fundamentals中文

Agios Pharmaceuticals: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 11, 2026 · Reflects: 10-K FY2025, the 10-Q for Q3 2026 and the Q3 2026 release (Nov 5, 2026)

Disclosure: one or more of our editors own shares of Alnylam (ALNY), named on this page, as a long-term investment. This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Nov 11, 2026. Reflects the 10-K for 2025, the 10-Q for Q3 2026 and the Q3 release and call (Nov 5).

Agios sells one drug, mitapivat, a pill that activates an enzyme called pyruvate kinase to help red blood cells survive longer in inherited anemias. It sells mitapivat as PYRUKYND for pyruvate kinase (PK) deficiency (US approval in 2022) and, since late January 2026, as AQVESME for thalassemia, under a Risk Evaluation and Mitigation Strategy (REMS), a safety program that requires liver tests. Revenue was $54.0M in 2025 and $55.4M in Q3 2026 alone, but the company still loses money, about $65M in Q3, and lives on the cash from selling its cancer business and royalties. It now targets profitability in 2028 on an adjusted (non-GAAP) basis, which leaves out some costs as Agios defines them. Agios describes its largest potential indication as sickle cell disease, about 100,000 people in the US, where the FDA has moved its decision to Feb 1, 2027.

Revenue $M Note
2025, mitapivat (PYRUKYND), total 54.0 All product revenue; no collaboration or royalty revenue
Q4 2025: US / outside the US 16.0 / 4.0 Q4 2025 release
Q2 2026: US / outside the US 40.9 / 3.8 After the thalassemia launch (Q2 2026 release)
Q3 2026: US / outside the US 48.7 / 6.6 Q3 2026 release

2. Story so far

Last updated Nov 11, 2026. Reflects filings and releases to Nov 5, 2026.

In short: Agios sold its cancer business in 2021 to focus on rare blood diseases, then used the cash for a large buyback and its own launches. Mitapivat is approved in PK deficiency and thalassemia, and sickle cell disease, its largest target, now waits until Feb 1, 2027 for an FDA decision. Both its thalassemia and sickle cell reviews were extended by three months over a safety program for liver risk.

Date Milestone Source
Mar 31, 2021 ★ Sells its oncology business to Servier for about $1.8B in cash plus a $200M payment if vorasidenib was approved, and royalties 10-K FY2025
2021 Buys back 16.2M shares for $802.5M 10-K FY2023
2022 FDA approves PYRUKYND for PK deficiency in adults FDA drug label
Jul 2023 Licenses AG-236, a small interfering RNA (siRNA) drug for polycythemia vera, from Alnylam 10-K FY2025
May–Sep 2024 Sells its vorasidenib royalty rights to Royalty Pharma for $905M; receives the $200M Servier milestone after vorasidenib’s FDA approval 10-K FY2025
Sep 4, 2025 FDA extends the thalassemia review by three months after Agios submits a proposed safety program (REMS) Agios release
Nov 2025 Sickle cell Phase 3 (RISE UP) meets its hemoglobin goal but not its pain-crisis goal 10-K FY2025
Dec 23, 2025 ★ FDA approves mitapivat for thalassemia, sold as AQVESME under a REMS 10-K FY2025
May–Jul 2026 Submits the sickle cell application (accelerated approval) in May; announces FDA acceptance and Priority Review on Jul 7, with a Nov 1, 2026 goal date 10-Q Q2 2026
May–Jul 2026 Licenses cevidoplenib from Oscotec ($25M upfront); stops tebapivat in two diseases; EU approves PYRUKYND for thalassemia Q2 2026 release
Oct 30, 2026 ★ FDA moves the sickle cell decision to Feb 1, 2027 after asking whether a REMS is needed. Our coverage: why Agios fell Agios release
Oct 30, 2026 Our coverage starts —
Nov 5, 2026 Q3 results: record sales of $55.4M; Agios expects research and development (R&D) headcount more than 35% below 2025 by year-end; goal of non-GAAP profitability in 2028 Q3 2026 release

3. Latest quarter: did the story change?

Last updated Nov 11, 2026. Reflects Q3 2026 (quarter to Sep 30, 2026), the release, 10-Q and call.

Bottom line: Sales rose 24% from Q2 and Agios set a 2028 non-GAAP profit goal while cutting R&D jobs, but prescription additions slowed and the sickle cell decision stays open until Feb 1, 2027.

Driver Last quarter → this quarter Management: before → now Signal
US mitapivat sales $40.9M (including about $5M of one-time stocking) → $48.7M No total revenue guidance → still none; deductions from gross sales (rebates and discounts) guided at 10–20% (July) Better
Sales outside the US $3.8M → $6.6M Early access programs in Europe Better
AQVESME prescriptions added 200 → 177 (619 in total, plus 48 in process) In July, said reporting would end after Q3 → cutoff reaffirmed Worse
Operating expenses Reported $155.3M → $132.5M; excluding Q2’s $25M upfront, $130.3M → $132.5M 2026 about flat vs 2025, excluding the upfront → also excluding about $11M of Q4 job-cut costs Unchanged
Profit goal None → non-GAAP profitability in 2028, including a potential 2027 sickle cell launch “Financial independence” kept; “opportunistically expand” the pipeline → “progress” it Better

Statements from the earnings calls are reported, from third-party transcripts.

What it means: thalassemia keeps lifting sales, and Agios now puts a date on profitability, but new prescriptions slowed in Q3 and the larger sickle cell opportunity still waits for the FDA.

Unresolved questions: whether the sickle cell label requires a REMS; how many AQVESME prescriptions turn into paying patients once Agios stops reporting the count; and what the R&D cuts save in 2027, which Agios has not quantified.

4. Buybacks vs real dilution (5 years)

Last updated Nov 11, 2026. Reflects the 10-K FY2023 and 10-K FY2025 (statements of stockholders’ equity) and the 10-Q for Q3 2026.

Dilution in one line: shares outstanding fell 15.7% from Dec 31, 2020 to Dec 31, 2025 (−3.3% a year, compounded).1 If you owned 1% of Agios at the end of 2020, you’d own 1.19% at the end of 2025 without buying more.2 Buybacks offset about 300% of the new shares.3 Our scale: Net reduction.

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2020 to Dec 31, 2025FY2021 −21.6%, FY2022 +1.3%, FY2023 +1.6%, FY2024 +2.2%, FY2025 +2.3%. Total −15.7% since Dec 31, 2020.−25%−20%−15%−10%−5%0%+5%FY2021: −21.6% in the period; −21.6% since Dec 31, 2020−21.6%FY2021FY2022: +1.3% in the period; −20.6% since Dec 31, 2020+1.3%FY2022FY2023: +1.6% in the period; −19.3% since Dec 31, 2020+1.6%FY2023FY2024: +2.2% in the period; −17.5% since Dec 31, 2020+2.2%FY2024FY2025: +2.3% in the period; −15.7% since Dec 31, 2020+2.3%FY2025−15.7%since Dec 31, 2020

Change in the period Total since Dec 31, 2020

Shares outstanding at period end (all classes): 69.3M on Dec 31, 2020, 58.4M on Dec 31, 2025, −15.7% (our calculation). A bar below zero means the count fell (net buybacks).

Latest quarter-end (Jun 30, 2026): 59.6M shares, +2.0% since Dec 31, 2025.

Shares outstanding (one class of common stock; treasury shares excluded).

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
FY2025 (Dec 31, 2025)58.4M+2.3%—$53M97%
FY2024 (Dec 31, 2024)57.2M+2.2%—$43M117%
FY2023 (Dec 31, 2023)55.9M+1.6%$0$45M167%
FY2022 (Dec 31, 2022)55.0M+1.3%$0$49M346%
FY2021 (Dec 31, 2021)54.3M−21.6%$802M$54M—
FY2020 (Dec 31, 2020)69.3M—$0$62M—

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

The 2021 buyback, paid for with the cancer-business sale, removed more shares than employee stock plans have added since. From 2022 the count has grown again, about 1.8% a year, all from employee equity plans.4

How we calculated this
Share bridge (millions) 2021 2022 2023 2024 2025 5-yr total
Start of year 69.29 54.33 55.04 55.95 57.16 69.29
+ Stock incentive plan and employee stock purchases 1.26 0.71 0.91 1.21 1.29 5.37
− Shares repurchased −16.22 0 0 0 0 −16.22
End of year 54.33 55.04 55.95 57.16 58.45 58.45
Stock-based pay, $M 53.5 49.3 44.8 42.8 52.6

Shares outstanding exclude the 16.2M treasury shares. Sources: equity statements in the 10-K FY2023 and 10-K FY2025. Shares outstanding were 59.78M on Sep 30, 2026, up 2.28% from year-end 2025, and 59.81M on Oct 30, 2026 (10-Q Q3 2026). Stock-based compensation was 97.3% of 2025 revenue (our calculation).5

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2021 16.22M $49.49 (our calculation)6 $802.5M — — — 10-K FY2023, statement of stockholders’ equity
2022 — — — — — — 10-K FY2023
2023 — — — — — — 10-K FY2023
2024 — — — — — — 10-K FY2025
2025 — — — — — — 10-K FY2025
2026 YTD (to Sep 30) — — — — — — 10-Q Q3 2026

No public offerings or at-the-market share sales are reported for this period; employee-plan proceeds are excluded. The 2021 buyback is the only repurchase.

Basis and details
  • The $1.2B buyback authorization of Mar 25, 2021 was used for $802.5M (XBRL company facts); no repurchases are reported after 2021.
  • Shares withheld for employee taxes are excluded from “bought back”.
  • Agios filed an automatic shelf registration (S-3ASR) on Feb 12, 2026, which allows share sales but is not committed money; no sales under it are disclosed.
  • No stock splits in the period.

Insider transactions: Form 4 filings show no open-market purchases by insiders in the 12 months to Oct 30, 2026, and sales of about $5.0M (transactions Oct 30, 2025 to Oct 26, 2026; the last was filed Oct 28).7

  • Most of the sales were automatic sales to cover taxes when stock awards vested, under Rule 10b5-1 trading plans, which set sales in advance.
  • The largest sellers were the chief medical officer (about $1.9M) and the chief executive (about $1.7M).
Insider details (Form 4, Oct 30, 2025 to Oct 26, 2026)
  • We read all 46 Form 4 filings listed on EDGAR from Oct 30, 2025 to Oct 30, 2026. Sales by person: Sarah Gheuens, chief medical officer, 56,443 shares (about $1.85M); Brian Goff, CEO, 55,826 (about $1.69M); Tsveta Milanova, chief commercial officer, 11,934 ($0.35M); James Burns, chief legal officer, 11,430 ($0.34M); Cecilia Jones, CFO, 11,108 ($0.33M); Theodore Washburn, principal accounting officer, 7,495 ($0.22M); Krishnan Viswanadhan, chief corporate development officer, 5,918 ($0.18M); David Scadden, director, 200.
  • Of 27 filings with sales, 20 describe sales to cover tax withholding under a 10b5-1 plan, 6 other 10b5-1 plan sales and 1 a sale without a plan reference.

5. Profit vs cash (latest FY and TTM)

Last updated Nov 11, 2026. Reflects the 10-K FY2025 and the 10-Q for Q3 2026. TTM = four quarters to Sep 30, 2026.

Agios loses roughly as much in cash as it reports in losses: stock pay is the only large non-cash cost, and the company has no debt.

$M 2025 TTM to Sep 20268
Net income under generally accepted accounting principles (GAAP) −412.8 −372.9
Operating cash flow −373.0 −331.7
Capital spending −4.3 −4.3
Free cash flow9 −377.3 −336.0

The Q3 release reports GAAP results and introduces a goal of non-GAAP profitability in 2028; it gives no historical adjusted net income.

Helps future profit or cash:

  • Product revenue: quarterly sales rose from $20.7M in Q1 to $55.4M in Q3 2026 after the thalassemia launch, while the quarterly net loss narrowed to $65.0M.
  • Agios expects R&D headcount to be more than 35% below 2025 by year-end; it has not quantified the 2027 savings.

Hurts future profit or cash:

  • Interest income is falling as cash is spent: $29.4M in the first nine months of 2026 against $44.0M a year earlier. It was $56.4M in all of 2025.
  • Stock-based pay ($52.6M in 2025; $48.2M in the first nine months of 2026) is not cash but adds shares.
  • The sickle cell FDA decision date was extended to Feb 1, 2027; launch timing remains subject to approval.

One-off / no lasting effect:

  • The $25M upfront for cevidoplenib (Q2 2026) is in research and development expense and in the loss; in the cash-flow statement it is an investing outflow.
  • Reported: about $11M of one-time costs for the R&D job cuts, which CFO Cecilia Jones expects in Q4 2026, according to the transcript of the Nov 5 call (Q3 call); no cash-payment date was given.
The raw reconciling items

Disclosed, 10-K FY2025 and 10-Q Q3 2026: net loss −$412.8M (2025) and −$264.9M (nine months 2026); stock-based compensation +$52.6M (2025) and +$48.2M (nine months 2026); operating cash flow −$373.0M (2025) and −$235.5M (nine months 2026); capital spending −$4.3M (2025) and −$3.2M (nine months 2026); interest income $56.4M (2025), $29.4M (nine months 2026). Nine-month operating cash use of $235.5M against a $264.9M net loss includes stock pay, the licensing-expense reclassification, lease items and working capital.

Funding: how long without new money? Cash-burning: $907.0M of cash, cash equivalents and marketable securities at Sep 30, 2026 covered about 10.8 quarters of the past year’s free cash outflow ($336.0M);10 there is no debt.

Agios Pharmaceuticals: cash runway, three views

At the past rate, cash would fall below zero around Q2 2029; using the company's spending guidance (our illustration), around Q1 2031.

−$500$0$500$1,000$1,500$2,000Q4 2024: $1,532MQ1 2025: $1,424.6MQ2 2025: $1,339.4MQ3 2025: $1,257.2MQ4 2025: $1,164.4MQ1 2026: $1,045.5MQ2 2026: $964.8MQ3 2026: $907Mactualpast rate: ~Q2 2029using guidance: ~Q1 2031Q4 2024202620272028202920302031−$500$0$500$1,000$1,500$2,000Q4 2024: $1,532MQ1 2025: $1,424.6MQ2 2025: $1,339.4MQ3 2025: $1,257.2MQ4 2025: $1,164.4MQ1 2026: $1,045.5MQ2 2026: $964.8MQ3 2026: $907Mactualpast rate: ~Q2 2029using guidance: ~Q1 2031Q4 202420272028202920302031

Cash, short-term investments and marketable debt securities, $M, at each quarter end

Agios does not give a cash-depletion date. It says existing cash and marketable securities, together with anticipated product revenue and interest income, support its launches and pipeline, and it targets non-GAAP profitability in 2028. Its Q3 2026 10-Q says existing resources are expected to fund current operations for at least the next twelve months.

Our calculation from company filings and guidance; illustrations, not forecasts.
  • At the past rate, spending is held flat; rising sales would stretch it and a sickle cell launch would add costs. Companies usually raise money well before that point.
  • Past rate: free cash outflow over the last 12 months ($336M) ÷ 4 = $84M a quarter.
  • Using company guidance (our calculation): a net outflow of $53.3M a quarter through Q4 2026, then carried forward. Guided items used: Operating expenses, FY2026 expected approximately flat versus FY2025, excluding the $25M cevidoplenib upfront and about $11M of Q4 job-cut costs; our cash proxy holds the guided total exactly flat (our assumption for "approximately flat"), not a full cash-flow forecast (it omits working capital) (Cecilia Jones, CFO, Q2 and Q3 2026 calls (Jul 30 and Nov 5, 2026); FY2025 actual: Q4 2025 release; nine-month 2026 actual: Q3 2026 10-Q).
  • Not guided, held at Q3 2026 levels: US product revenue (PYRUKYND and AQVESME) $48.7M a quarter (includes US PK deficiency sales, which the CFO guided at about $45–50M for 2026 on the Q1 2026 call, Apr 29, 2026); Revenue outside the US $6.6M a quarter; Interest income $8.9M a quarter (held flat although falling cash would lower it, so this may overstate the runway); Capital spending $1.1M a quarter (the nine-month 2026 quarterly average).
  • No dated known items (debt maturities, scheduled payments or completed raises).
  • Not included (conditional or undated): Oscotec cevidoplenib development and regulatory milestones of up to $140M (Phase 3 start planned 1H 2028); Alnylam AG-236 development and regulatory milestones of up to $120M; Inflow: 3% of US vorasidenib net sales above $1.0B a year (retained earn-out).
Show the data table
QuarterActual ($M)At the past rate ($M)Using company guidance (our calculation, $M)
Q4 20241,532
Q1 20251,424.6
Q2 20251,339.4
Q3 20251,257.2
Q4 20251,164.4
Q1 20261,045.5
Q2 2026964.8
Q3 2026907907907
Q4 2026823853.7
Q1 2027739800.4
Q2 2027655747.2
Q3 2027571.1693.9
Q4 2027487.1640.6
Q1 2028403.1587.3
Q2 2028319.1534
Q3 2028235.1480.7
Q4 2028151.1427.4
Q1 202967.1374.2
Q2 2029-16.9320.9
Q3 2029267.6
Q4 2029214.3
Q1 2030161
Q2 2030107.7
Q3 203054.4
Q4 20301.2
Q1 2031-52.1
Funding details
  • This is based on past cash flow; spending plans can change it. Agios says existing cash and marketable securities, together with anticipated product revenue and interest income, support its launches and pipeline, and it targets non-GAAP profitability in 2028 (Q3 2026 release). Its 10-Q says existing resources are expected to fund current operations for at least the next twelve months (10-Q Q3 2026).
  • Sources: 10-Q Q3 2026, balance sheet and cash-flow statement.

Extends the runway:

  • No committed financing. The Feb 2026 shelf registration allows share sales but is not committed money.

Shortens the runway:

  • No debt maturities.

Conditional:

  • Up to an additional $120M of development and regulatory milestones remained payable to Alnylam for AG-236 at Dec 31, 2025, following a $10M milestone payment in 2025, plus sales milestones and royalties (10-K FY2025).
  • Up to $140M of development and regulatory milestones payable to Oscotec for cevidoplenib, plus sales milestones and royalties (10-Q Q2 2026).
  • Possible inflow: Agios retains a 3% royalty on the portion of annual US net sales of vorasidenib exceeding $1.0B (10-K FY2025). It recognized $3.0M of this retained royalty income in Q3 2026 (10-Q Q3 2026).

6. Customer and contract exposure

Last updated Nov 11, 2026. Reflects the 10-K FY2025 and the 10-Q for Q3 2026.

One unnamed customer accounted for 89% of Agios’s 2025 revenue, so nearly all sales run through a single distributor or pharmacy; its other contracts mainly set future pipeline costs.

Customer and contract details
  • Customers: Agios sells PYRUKYND and AQVESME in the US “to a limited number of specialty distributors and specialty pharmacy providers”, and outside the US to Avanzanite and NewBridge (10-K FY2025). One unnamed customer accounted for 89%, 95% and 96% of revenue in 2025, 2024 and 2023, respectively (Note 10).
  • REMS: AQVESME is available only through a REMS that requires liver tests before the first dose and every four weeks for 24 weeks, plus patient enrollment and certification of prescribers and pharmacies. PYRUKYND for PK deficiency does not require a REMS (10-K FY2025).
  • Alnylam (AG-236, licensed in 2023): up to an additional $120M of development and regulatory milestones at Dec 31, 2025 (after a $10M payment in 2025), plus sales milestones and tiered royalties (10-K FY2025).
  • Oscotec (cevidoplenib, licensed in 2026): $25M upfront, up to $140M of development and regulatory milestones, plus sales milestones and royalties; Oscotec can opt in for South Korea (10-Q Q2 2026).
  • Royalty Pharma and Servier: Royalty Pharma owns the vorasidenib royalties Agios sold in 2024 for $905M; Agios retains a 3% royalty on the portion of annual US net sales of vorasidenib exceeding $1.0B (10-K FY2025). It recognized $2.969M of this retained royalty income in Q3 2026 (10-Q Q3 2026).
  • Generic challenge: Annora Pharma has filed an abbreviated new drug application (ANDA) for a generic PYRUKYND. Agios says its patent infringement suit prevents FDA approval until at least the earlier of Aug 17, 2029, or a judgment finding the asserted patents invalid, unenforceable or not infringed. The composition-of-matter patent (to 2035) is not challenged. The USPTO issued a discretionary denial of an inter partes review request on US 11,878,049 on Sep 23, 2026. Opponents appealed decisions upholding two European mitapivat patents (not the primary compound patent); hearings are set for April and September 2027 (10-Q Q3 2026).
  • NewBridge, its Gulf distribution partner, was acquired by DKSH in October 2026 (10-Q Q3 2026).
  • Customer concentration: the figures above are for FY2025; the Q3 10-Q gives no update.

7. Agios’s strategy for long-term growth

Last updated Nov 11, 2026. Reflects the 10-K FY2025, the 10-Q for Q3 2026 and the Q3 release and call.

Agios is betting on one molecule in more blood diseases plus a few licensed drugs; so far the new uses bring growth, while the thalassemia and sickle cell reviews required additional safety-related submissions.

  • Pressures on the core business: mitapivat is a one-drug business today. Its patents have statutory expiry dates of “at least 2030 to 2042” (10-K FY2025). In thalassemia and, possibly, sickle cell disease, the liver-injury risk means a REMS with regular liver tests.
  • The strategy in management’s words: “strong commercial momentum, pipeline diversification, and strategic portfolio discipline” (CEO Brian Goff, Q2 2026 release). The steps so far:
    • selling the cancer business (2021) and the vorasidenib royalties (2024) for cash;
    • an $802.5M buyback in 2021;
    • licensing AG-236 from Alnylam (2023) and cevidoplenib from Oscotec (2026);
    • stopping tebapivat in lower-risk myelodysplastic syndromes (MDS) and sickle cell disease after Phase 2 results (2026);
    • cutting R&D headcount by more than 35% versus 2025 by year-end, concentrating clinical investment in rare hematology and exploring value from non-core assets, including AG-181 and the vorasidenib royalty (reported, Q3 call).
  • How well it is working, in numbers:
    • mitapivat revenue rose from $54.0M in 2025 to $120.9M in the first nine months of 2026 alone, after the thalassemia launch;
    • 619 AQVESME prescriptions by Sep 30, 2026, plus 48 in process; about 75% of patients remain on AQVESME after six months, the company says (persistence, not efficacy);
    • a goal of non-GAAP profitability in 2028, including a potential 2027 sickle cell launch;
    • target populations, company estimates: about 4,000 thalassemia patients at launch; about 75,000 diagnosed US sickle cell patients aged 16 and older, with an initial focus on about 25,000, subject to approval (reported, Q3 call);
    • the sickle cell decision moved from Nov 1, 2026 to Feb 1, 2027;
    • Agios has not given total revenue targets. It says cevidoplenib could reach “up to $1.0 billion in peak U.S. sales” in immune thrombocytopenia (company estimate; Phase 3 start planned for 1H 2028).
  • What to watch: the sickle cell label and whether it carries a REMS; the REIGNITE confirmatory trial; the ENERGIZE-Kids and ENERGIZE-Kids-T pediatric thalassemia trials, which are enrolling; the AG-236 Phase 2/3 start in polycythemia vera and AG-181 Phase 1b data in phenylketonuria (both by year-end 2026).

8. What to watch

Last updated Nov 11, 2026.

Date Item Source
Year-end 2026 Start of a Phase 2/3 program of AG-236 in polycythemia vera; Phase 1b proof-of-mechanism data for AG-181 in phenylketonuria Q3 call (reported)
Dec 12–15, 2026 ASH annual meeting: 14 accepted abstracts, including new mitapivat data in sickle cell disease and the first clinical data for AG-236 Q3 2026 release
Before Feb 1, 2027 Labeling talks with the FDA on sickle cell disease, “including elements of a potential REMS” Agios release
Feb 1, 2027 FDA goal date for mitapivat in sickle cell disease (accelerated approval, Priority Review) Agios release
1H 2028 Planned Phase 3 start for cevidoplenib in immune thrombocytopenia Q2 2026 release

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 30, 2026$30.55 (Oct 30)$1.8B$856M18.5×8.7×n/mn/m+141%−371%$965M12 months to Jun 30, 2026
Nov 11, 2026$31.76 (Nov 10)$1.9B$993M13.5×7.0×n/mn/m+214%−238%$907M12 months to Sep 30, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 30, 2026 price: official close, Nasdaq (Stock Analysis daily history). Nov 11, 2026 price: official close, Nasdaq, Yahoo Finance.

Notes and calculations

  1. On year-end shares outstanding: 58.449M ÷ 69.294M − 1 = −15.7%; yearly = (58.449 ÷ 69.294)^(1/5) − 1 = −3.3%. ↩

  2. 69.294M ÷ 58.449M × 1%. ↩

  3. Shares repurchased ÷ new shares issued, 2021–2025: 16.216M ÷ 5.371M ≈ 302%. ↩

  4. (58.449M ÷ 54.334M)^(1/4) − 1 ≈ 1.8% a year, Dec 31, 2021 to Dec 31, 2025. ↩

  5. $52.552M ÷ $54.028M × 100. ↩

  6. $802.486M ÷ 16.216411M shares. ↩

  7. Sum of shares × reported price for transaction code S in the Form 4 filings filed Oct 30, 2025 to Oct 30, 2026 (transaction dates to Oct 26, 2026) ≈ $4.98M; no code P (purchase) transactions. ↩

  8. FY2025 − nine months 2025 + nine months 2026. Net loss: −$412.8M + $304.7M − $264.9M; operating cash flow: −$373.0M + $276.8M − $235.5M; capital spending: −$4.3M + $3.2M − $3.2M. ↩

  9. Operating cash flow + capital spending. ↩

  10. $907.0M ÷ ($336.0M ÷ 4 per quarter) ≈ 10.8 quarters. ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Agios Pharmaceuticals: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)